肝癌患者血清中肿瘤特异性生长因子水平与临床病理特征及预后的关系_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 程黎

重庆三峡中心医院肝胆外科（重庆万州 404100）;

Corresponding author：

程黎, Email: cqchengli@163.com

Keywords：

肝细胞癌; 肿瘤特异性生长因子; 临床病理特征; 预后

DOI：

10.7507/1007-9424.20150260

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的探讨肝细胞癌（简称“肝癌”）患者血清中肿瘤特异性生长因子（TSGF）水平与患者临床病理特征及预后的关系。方法选取2010年1月至2013年12月期间我院收治的76例行手术治疗的肝癌患者（肝癌组）和45例正常健康体检者（对照组），比较2组间血清TSGF水平，并观察血清TSGF水平与肝癌患者的临床病理特征和预后之间的关系。结果肝癌组血清TSGF水平为（86.25±10.52）U/mL，表达阳性率为76.32%（58/76），均明显高于对照组的（25.32±6.54）U/mL和6.67%（3/45），差异有统计学意义（t=35.019，P＜0.001；χ²=52.097，P＜0.001）。血清TSGF水平与肝癌患者有无癌栓、TNM分期、组织分化程度、有无肝硬变有关（均P＜0.05）。血清TSGF水平阳性表达者3年总生存率为55.0%，明显低于阴性表达者的3年总生存率（85.7%），两者之间比较差异有统计学意义（χ²=4.502，P=0.034）。结论 TSGF在肝癌患者血清中高表达，与有无癌栓、TNM分期、组织分化程度、有无肝硬变有关，且其表达高者预后差，有助于肝癌的诊断和预后评价。

Citation： 程黎. 肝癌患者血清中肿瘤特异性生长因子水平与临床病理特征及预后的关系. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(8): 995-997. doi: 10.7507/1007-9424.20150260 Copy

1.	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822):1245-1255.
2.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
3.	Lu W, Dong J, Huang Z, et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma under-going curative resection:Okuda, CLIP, TNM and CUPI. J Gastroen-terol Hepatol, 2008, 23(12):1874-1878.
4.	王君哲, 牟君成, 范慧, 等.血清肿瘤相关物质检测在恶性肿瘤诊断中的应用价值.重庆医学, 2010, 39(11):1418-1419.
5.	陈芳华, 骆曦, 饶万楷.恶性肿瘤特异性生长因子对恶性肿瘤的诊断价值.国际检验医学杂志, 2011, 32(11):1183-1184, 1186.
6.	周琦, 张琼, 魏来.血清甲胎蛋白、肿瘤相关物质和癌胚抗原对原发性肝癌的鉴别诊断.世界华人消化杂志, 2010, 18(18):1936-1939.
7.	康从利, 徐日, 徐风亮, 等.血清肿瘤标志物的联合动态检测在原发性肝癌诊断中的价值.肿瘤研究与临床, 2014, 26(8):531-534, 538.
8.	赵建军, 阎涛, 黄振, 等.中国肝细胞癌患者最佳分期系统探讨.中华医学杂志, 2014, 94(12):903-907.
9.	Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci, 2014, 15(6):9546-9565.
10.	Chen Y, Gao SG, Chen JM, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2014 Dec 9.[Epub ahead of print].
11.	孟冬娅, 胡晓芳, 高洪福, 等.检测血清VEGF、CEA、TSGF在肿瘤中的临床意义.中国现代医学杂志, 2004, 14(1):117-118.
12.	原晓勇, 吴斌.血清TSGF在乳腺癌中的研究现状.现代临床医学, 2011, 37(2):83-84.
13.	Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommenda-tions for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Onco-logy. J Clin Oncol, 2001, 19(6):1865-1878.
14.	王建俊, 王金鹏.血清TSGF和CA199联检对肝硬化的诊断价值的研究.医学检验与临床, 2011, 22(4):18-19.
15.	Karaman B, Battal B, Sari S, et al. Hepatocellular carcinoma review:current treatment, and evidence-based medicine. World J Gastroen-terol, 2014, 20(47):18059-18060.

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822):1245-1255.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
3. Lu W, Dong J, Huang Z, et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma under-going curative resection:Okuda, CLIP, TNM and CUPI. J Gastroen-terol Hepatol, 2008, 23(12):1874-1878.
4. 王君哲, 牟君成, 范慧, 等.血清肿瘤相关物质检测在恶性肿瘤诊断中的应用价值.重庆医学, 2010, 39(11):1418-1419.
5. 陈芳华, 骆曦, 饶万楷.恶性肿瘤特异性生长因子对恶性肿瘤的诊断价值.国际检验医学杂志, 2011, 32(11):1183-1184, 1186.
6. 周琦, 张琼, 魏来.血清甲胎蛋白、肿瘤相关物质和癌胚抗原对原发性肝癌的鉴别诊断.世界华人消化杂志, 2010, 18(18):1936-1939.
7. 康从利, 徐日, 徐风亮, 等.血清肿瘤标志物的联合动态检测在原发性肝癌诊断中的价值.肿瘤研究与临床, 2014, 26(8):531-534, 538.
8. 赵建军, 阎涛, 黄振, 等.中国肝细胞癌患者最佳分期系统探讨.中华医学杂志, 2014, 94(12):903-907.
9. Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci, 2014, 15(6):9546-9565.
10. Chen Y, Gao SG, Chen JM, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2014 Dec 9.[Epub ahead of print].
11. 孟冬娅, 胡晓芳, 高洪福, 等.检测血清VEGF、CEA、TSGF在肿瘤中的临床意义.中国现代医学杂志, 2004, 14(1):117-118.
12. 原晓勇, 吴斌.血清TSGF在乳腺癌中的研究现状.现代临床医学, 2011, 37(2):83-84.
13. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommenda-tions for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Onco-logy. J Clin Oncol, 2001, 19(6):1865-1878.
14. 王建俊, 王金鹏.血清TSGF和CA199联检对肝硬化的诊断价值的研究.医学检验与临床, 2011, 22(4):18-19.
15. Karaman B, Battal B, Sari S, et al. Hepatocellular carcinoma review:current treatment, and evidence-based medicine. World J Gastroen-terol, 2014, 20(47):18059-18060.

Previous Article
暴饮暴食致急性胃扩张并胃坏死破裂1例报道
Next Article
腹壁复发切口疝的微创治疗体会

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

肝癌患者血清中肿瘤特异性生长因子水平与临床病理特征及预后的关系

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content